Wednesday, June 27, 2012

Xoma enrolling 2 trials, in eye disease and osteoarthritis

Both trials center on the Berkeley-based biotech company's (NASDAQ: XOMA) experimental monoclonal antibody treatment, called gevokizumab.
"Today represents an historic milestone for Xoma, as we launch the first global Phase III program for a Xoma-created product to which we retain U.S. commercial rights," CEO John Varian said in a press release.

No comments:

Post a Comment